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ABSTRACT  36 
Background 37 
A main criterion to identify malaria vaccine candidates is the proof that acquired immunity 38 
against them is associated with protection from disease. The age of the studied individuals, 39 
heterogeneous malaria exposure and assumption of the maintenance of a baseline immune 40 
response can confound these associations. 41 
 42 
Methods 43 
IgG/IgM levels were measured by Luminex® in Mozambican children monitored for clinical 44 
malaria from birth until 3 years of age, together with functional antibodies. Studied 45 
candidates were pre-erythrocytic and erythrocytic antigens, including EBAs/PfRhs, MSPs, 46 
DBLs, and novel antigens merely or not previously studied in malaria-exposed populations. 47 
Cox regression models were estimated at 9 and 24 months of age, accounting for 48 
heterogeneous malaria exposure or limiting follow-up according to the antibody’s decay. 49 
 50 
Results 51 
Associations of antibody responses with higher clinical malaria risk were avoided when 52 
accounting for heterogeneous malaria exposure or when limiting the follow-up time in the 53 
analyses. Associations with reduced risk of clinical malaria were found only at 24 months old, 54 
but not younger children, for IgG breadth and levels of IgG targeting EBA140III-V, CyRPA, 55 
DBL5ε and DBL3x, together with C1q-fixation activity by antibodies targeting MSP119. 56 
 57 
Conclusions 58 
Malaria protection correlates were identified, only in children aged 24 months old when 59 
accounting for heterogeneous malaria exposure. These results highlight the relevance of 60 
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considering age and malaria exposure, as well as the importance of not assuming the 61 
maintenance of a baseline immune response throughout the follow-up. Results may be 62 
misleading if these factors are not considered.  63 64 
  4 
INTRODUCTION 65 
Since 2007, many efforts are focused on malaria elimination, with many settings reporting a 66 
dramatic decline in malaria cases. A highly efficacious vaccine could supplement the waning 67 
naturally acquired immunity (NAI) against malaria in these areas. Given the limited protection 68 
conferred by RTS,S vaccination[1], second-generation vaccines are an urgent requirement. 69 
A crucial criterion to identify malaria vaccine candidates is not only the validation of a specific 70 
antigen as target of NAI but also the confirmation that this immune response is associated 71 
with reduced risk of disease in the target population.  72 
 73 
Importantly, malaria cases are not equally distributed in endemic countries. This 74 
geographical disparity is observed at all transmission levels[2-4] and can be as pronounced 75 
as between households in the same village[4]. Variations in local transmission intensity and 76 
differential mosquito attraction seem to be major reasons for this heterogeneity in malaria 77 
exposure[5]. This phenomenon has major implications when studying correlates of 78 
protection, since unexposed individuals can be erroneously considered as protected[5,6]. In 79 
fact, inconsistent results are commonly found in the literature, where antibodies against the 80 
same antigen in similar populations are differentially associated with protection[7-13]. These 81 
discrepancies might be partially explained by the confounding effect of heterogeneous 82 
malaria exposure, together with the age of the studied population, as shown by several 83 
studies highlighting the role of age in protective immunity[14]. 84 
 85 
Previous approaches to account for heterogeneous malaria exposure are mainly focused on 86 
excluding malaria-unexposed individuals from the analyses[15-17]. Blood-stage infection at 87 
any time during the follow-up is the most common indicator of exposure. However, this 88 
methodology is logistically costly and is largely used in short-term follow-ups, given that it 89 
requires active case detection (ACD)[15]. Besides, it frequently implies the case treatment, 90 
limiting the identification of correlates of protection from symptomatic disease. For long-term 91 
follow-ups, in addition to blood-stage infection, clinical episodes have also been used as an 92 
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exposure indicator[17]. However, even focusing the analyses in those individuals reporting 93 
an infection and/or clinical episode during the follow-up, the microheterogeneity in the 94 
exposure level can affect the rate of immunity acquisition and consequently the identification 95 
of protective correlates. Therefore, it is not only important to focus the analyses on malaria-96 
exposed individuals, but also to consider the exposure level, indicated by serology, clinical or 97 
demographic data. Similarly, results from longitudinal studies can also be confounded by the 98 
long follow-ups during which the outcome can occur, according to the assumption that the 99 
immune responses at baseline represent a stable measure of immune competence[6]. 100 
Hence, the follow-up of a longitudinal study can be higher than the actual time that the 101 
specific antibodies remain in blood, at least, at protective levels[6,18]. Approaches to control 102 
these phenomena are thought to contribute to a deeper understanding of NAI against 103 
vaccine candidates.  104 
 105 
We hypothesized that correlates of protection are better identified when studying only 106 
malaria-exposed individuals, when limiting the follow-up time according to the antibodies’ 107 
decay and in older compared to younger children. To address this, we analyzed antibody 108 
responses and their functionality to Plasmodium falciparum antigens and assessed the 109 
association with clinical malaria risk in Mozambican children. The antigens studied are 110 
expressed during pre-erythrocytic and erythrocytic stages, including Erythrocyte-Binding 111 
Antigens (EBAs), P. falciparum Reticulocyte-binding Homologs (PfRhs), Merozoite Surface 112 
Proteins (MSPs) and novel antigens scarcely or not tested yet in longitudinal studies, namely 113 
P41, AARP (Apical Asparagine-Rich Protein) or CyRPA (Cysteine-Rich Protective Antigen).  114 115 Con formato: Título 1, Justificado
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METHODS 116 
Study area and population 117 
The study was conducted in the Manhiça District, southern Mozambique[19], where a 118 
demographic surveillance system (DSS) provides accurate information on its population (see 119 
supplementary methods). Malaria transmission is perennial with some seasonality, coinciding 120 
with the rainy season (November-April). P. falciparum and Anopheles funestus are the 121 
predominant species and vector, respectively. Entomological inoculation rate in 2002 was 38 122 
infective bites/person/year[19]. 123 
 124 
Study population comprised children from three cohorts studied between 2002 and 2007, in 125 
placebo-controlled trials (see supplementary methods and[20-22]). Children from the placebo 126 
arm of each cohort were selected to exclude the effect of any intervention in the acquisition 127 
of immunity. Briefly, cohort A[20] involved newborns followed from birth until 2 years of age 128 
(cross-sectional visits at 0, 2.5, 5.5, 10.5, 15 and 24 months). Cohort B[22] included children 129 
enrolled at 5 months old who underwent cross-sectional visits at 5, 9, 12 and 24 months. 130 
Finally, cohort C[21] involved newborns followed from birth until 12 months of age (cross-131 
sectional visits at 0, 3, 9 and 12 months). For cohorts A and C, information about maternal 132 
malaria infections (peripheral and placental -acute, chronic, past-) was available, together 133 
with maternally-transferred antibodies (measured in cord blood). Infections were detected by 134 
microscopy (OM) and malaria episodes by passive case detection (PCD, except for cohort A, 135 
see supplementary methods). The National Mozambican and the Hospital Clínic of 136 
Barcelona Ethics Review Committees approved these studies. Written informed consent was 137 
signed at enrollment.  138 
 139 
Antibody measurement  140 
 141 
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AARP, PTRAMP (Plasmodium Thrombospondin-Related Apical Merozoite Protein), MSP119, 142 
MSP3, PfRh1, PfRh240, PfRh430, PfRh490, PfRh5, CyRPA, P41, VAR2CSA Duffy Binding-143 
Like domains (DBL3X, DBL5ε and DBL6ε), DBLα (CR1-binding minimal domain from the 144 
R29var1 PfEMP1), PfRh22030-2528, EBA175-PfF2, regions III-V of EBA175 (EBA175III-V) and 145 
EBA140 (EBA140III-V), and pre-erythrocytic antigens CSP (Circumsporozoite Protein), LSA1 146 
(Liver Stage Antigen-1) and TRAP (Thrombospondin-Related Anonymous Protein) were 147 
produced in E. coli; AMA1 (Apical membrane antigen-1) in Pichia pastoris and gSG6-P1 148 
(peptide from mosquito saliva) was synthesized by GenScript (see supplementary Table 1 149 
and [23-30]). IgG and IgM responses were determined using Luminex xMAP™ beads (see 150 
supplementary methods). Briefly, multiplexed beads[31] were incubated with plasma 151 
samples, and antibody levels were measured as described elsewhere[31]. Positive, negative 152 
and background controls were added to each plate. Net Median Fluorescence Intensity (MFI) 153 
was obtained by subtracting blank values and prior to inter-plate normalization. Negative MFI 154 
values were substituted by the half-value of the minimum positive value for log-155 
transformation. 156 
 157 
Functional assays 158 
In a subset of children with available samples (n=67), functional features of merozoite-159 
specific antibodies at 24 months were studied. Opsonic phagocytosis (OPA)[32] and 160 
complement fixation assays (CFA)[33] are detailed in supplementary methods. Briefly, for 161 
OPA, freshly isolated merozoites were ethidium bromide-stained and incubated with plasma 162 
samples. THP-1 monocytes were added after opsonization. The number of THP-1 cells with 163 
internalized merozoites was determined by flow cytometry and the ratio to a positive control 164 
value was reported as the relative phagocytosis index (RPI%). In CFA, plates were coated 165 
with MSP119 or MSP3, and plasma samples incubated to allow antibody:antigen recognition. 166 
Human C1q was added, detected and its binding was measured by Optic Density. 167 
 168 
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Definitions and statistical analysis 169 
Cross-sectional samples were grouped as follows: birth (cohort A and B); 2.5 months (cohort 170 
A); 5 months (cohort A -5.5 months-, cohort B -3 months-, cohort C -5 months-); 9 months 171 
(cohort A -10.5 months-, cohort B -9 months-, cohort C -9 months-); 12 months (cohort A -15 172 
months-, cohort B -12 months, cohort C -12 months-); and 24 months (cohorts A and C). 173 
Clinical malaria was defined as axillary temperature ≥37.5ºC or reported fever in the 174 
preceding 24 hours with positive parasitemia by OM. Children were not considered at risk of 175 
malaria after 28 days of reporting an episode. 176 
 177 
Seropositive threshold was defined by the mean plus 3 standard deviation of IgG and IgM 178 
antibody levels of 82 and 85 Spanish naïve donors, respectively. Breadth of antibody 179 
responses was determined by the sum of seropositive responses for each child. Malaria-180 
exposed individuals were those that met, at least, one of the following criteria during the 181 
follow-up: report a previous P. falciparum infection or clinical episode; being seropositive for 182 
IgM levels against the pre-erythrocytic antigens CSP or LSA1; or a mother with reported 183 
infection during pregnancy (placental or peripheral).  184 
 185 
Parametric or non-parametric tests were applied according to the variables distribution. 186 
Wilcoxon rank-sum (or Kruskal-Wallis) and chi-square tests were used to compare means or 187 
prevalence between groups, respectively. Correlation between variables were assessed by 188 
Spearman’s correlation test.  189 
 190 
To study the effect of age and infection on antibody levels, we performed crude and adjusted 191 
linear regression models. Cox proportional hazard models were used to calculate hazard 192 
ratios (HR) of clinical malaria. To test the hypothesis that protective associations of 193 
antibodies differ with age, we compared the HR in children at 9 and 24 months of age during 194 
a year follow-up. To compare the importance of accounting for malaria-exposure 195 
heterogeneity, two Cox models were estimated: (i) adjusted by infection at sampling, age, 196 
  9 
gender, neighborhood of residence and cohort and (ii) limited to malaria-exposed individuals 197 
and adjusted by covariates specified in (i) and by exposure variables: IgM levels at sampling 198 
against pre-erythrocytic antigens; IgM levels against a mosquito saliva antigen (gSG6-P1) at 199 
sampling; and the number of previous malaria episodes. IgM adjustments were not done 200 
when analyzing IgM or functional immune responses’ association with clinical malaria risk. 201 
Hazards proportionality was evaluated by studying the Schoenfeld residuals. The time to 202 
25% of baseline (birth) antibody levels were estimated using linear mixed-effect regression 203 
models with data from birth to 5 months from children without infection or clinical episode 204 
during that time. These estimated times were used to limit the follow-up in Cox regression 205 
models when indicated. 206 
 207 
P-values were corrected by the Benjamini-Hochberg procedure[34]. Statistical analyses were 208 
performed using Stata version 14 (StataCorp. College Station, TX, USA) and graphs with 209 
Prism7 (GraphPad) and R Core Team (2016, Vienna, Austria). 210 211 
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RESULTS 212 
Antibody dynamics during the first two years of life 213 
A total of 1142 samples were tested for IgG and IgM against 23 P. falciparum antigens. 214 
Characteristics of children studied in each cross-sectional visit are specified in Table 1.  215 
Maternal IgG antibodies (measured in the newborns) were, in general, lost during the first 216 
months up to 5 months of age when the antibody responses increased again. As expected, 217 
IgM antibody responses increased since birth (Figure 1). Main determinants of antibody 218 
levels in children from 5 months old were infection at sampling and age (Supplementary 219 
Table 2). 220 
 221 
Association of antibody responses with risk of clinical malaria 222 
Malaria-exposed children represented 84.2% of the studied population at 9 months old (208 223 
out of 247) and 83.1% at 24 months of age (148 out of 178). Malaria-exposed children had 224 
higher breadth of IgG and IgM antibody responses at 9 and 24 months old compared to 225 
children considered non-exposed (Wilcoxon rank-sum test, p<0.001).  226 
 227 
In order to identify correlates of protection while studying the importance of accounting for 228 
heterogeneous malaria exposure, Cox regression models adjusted by P. falciparum infection, 229 
gender, age, neighborhood of residence and cohort were compared to models estimated 230 
after accounting for malaria exposure. At 9 and 24 months of age, initial models showed 231 
significant associations of IgG and IgM levels with higher risk of clinical malaria (HR>1). 232 
However, when considering malaria exposure, these associations with increased risk 233 
disappeared, and protective associations emerged, only at 24 months of age. Breadth of IgG 234 
antibody responses was associated with a slightly reduced risk of clinical malaria (HR 0.93 235 
[95% Confidence Interval 0.89, 0.97]; p=0.015). There were stronger protective associations 236 
for IgGs against CyRPA (HR 0.57 [95% CI 0.39, 0.83]; p=0.017), EBA140III-V (HR 0.55 [95% 237 
CI 0.39, 0.79]; p=0.009), DBL3x (HR 0.60 [95% CI 0.44, 0.81]; p=0.009) and DBL5ε (HR 0.55 238 
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[95% CI 0.40, 0.77]; p=0.009) (Figure 2). The specific antibodies differentially associated with 239 
reduced risk at 24 versus 9 months of age were not necessarily higher in the older group, 240 
being this the case for IgGs against CyRPA, DBL3X and DBL5ε (Wilcoxon rank-sum test, 241 
p>0.050). In contrast, no association of specific IgMs with reduced risk was observed once 242 
malaria exposure was considered. Some associations with higher clinical malaria risk were 243 
still found (although lost after multiple comparisons correction, Supplementary Figure 1). 244 
 245 
We also hypothesized that limiting the follow-up time according to the antibody’s decay 246 
would allow to better identify correlates of protection. The time to 25% of baseline levels was 247 
calculated for all the specific IgGs (Figure 3). This time ranged from 78 (95% CI [92, 64]; 248 
p<0.001) for PTRAMP to 550 days (95%CI [397, 703]; p<0.001) for P41. These times were 249 
used to limit the follow-up time in Cox regression models. As shown in Supplementary Figure 250 
2, this approach allowed to decrease the number of significant associations of specific 251 
antibodies with higher risk of clinical disease in standard analyses, but not when 252 
heterogeneity in malaria exposure was considered. 253 
 254 
Functional immune responses 255 
For a subset of children at 24 months of age (n=67), we analyzed the capacity of (i) 256 
phagocytosis induction by antibodies targeting merozoites and (ii) C1q fixation by MSP19 and 257 
MSP3-specific antibodies. Association of C1q fixation with reduced malaria risk was found 258 
only for MSP19 when considering malaria exposure (HR 0.11 [95% CI 0.02, 0.57]; p=0.009; 259 
n=45), but not for MSP3 specific antibodies (HR 0.5 [95% CI 0.2, 1.3); p=0.143). MSP119 nor 260 
MSP3-specific antibodies were associated with protection in this subset (p=0.994 and 0.922, 261 
respectively). Their C1q-fixation activity did not correlate for MSP119-specific antibodies, in 262 
contrast to antibodies targeting MSP3 (Spearman’s rho=0.37, p<0.001 for IgG and 263 
rho=0.212, p=0.03 for IgM). RPI increased with increasing breadth of IgG responses 264 
(Spearman’s rho=0.47, p-value<0.001), and was significantly higher in those children 265 
considered exposed compared to those considered non-exposed (Wilcoxon rank-sum test, 266 
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p<0.001). However, RPI was not associated with reduced risk of clinical malaria even when 267 
considering malaria exposure.  268 
  13 
DISCUSSION 269 
In this study, we describe the dynamics of antibody responses against P. falciparum antigens 270 
in the first two years of life, and report correlates of protective immunity in children from 271 
Mozambique. This is the first study to point the association of antibodies targeting CyRPA 272 
and AARP with reduced malaria risk and to assess functionality of antibody responses in 273 
such young children. 274 
 275 
Studies restricted to infants are considered less adequate to analyze correlates of protection 276 
given the confounding effect of in utero exposure and maternal transferred antibodies. 277 
However, this study is focused in children old enough to have lost maternal antibodies and 278 
built their own immunity, but young enough to still be the target population of routine 279 
vaccinations. It is known that antibodies need a mature immune system to perform certain 280 
functions[35], reason that can explain the lack of protective associations at 9 months 281 
compared to 24 months of age, as well as discrepancies with other studies with older 282 
children[13,32,33]. It is possible that specific antibody levels at 9 months are below protective 283 
thresholds[18], compared to 24 months. The protective threshold can be defined by intrinsic 284 
immune system features changing with age, as previously suggested[14]. This observation is 285 
in agreement with studies describing higher RTS,S vaccine efficacy in older children[1].  286 
 287 
IgGs targeting CyRPA, DBL3x, DBL5ε, EBA140III-V were associated with reduced clinical 288 
malaria risk at 24 months of age, in addition to AARP, DBLα, LSA1, PfRh2030 and P41, that 289 
lost significance after multiple comparisons correction. Some of them have already been 290 
shown as correlates of protection[13], but CyRPA and AARP are shown as correlates of 291 
protection for the first time. Unexpectedly, association of antibodies against DBL5ε, a 292 
VAR2CSA domain which binds to Chondroitin Sulphate A (CSA), with lower malaria risk was 293 
consistently found. P. falciparum-infected erythrocytes binding to CSA was first reported in 294 
pediatric isolates[36], suggesting the possible contribution of CSA-binding to malaria 295 
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infection and disease in children[37]. However, we cannot discard DBL5ε-specific antibodies 296 
as markers of other immune effectors responsible for such observation. We did not identify 297 
PfRh5-specific antibodies as correlates of protection, as previously reported[13]. These 298 
antibodies can act through the disruption of the PfRh5/CyRPA/Ripr complex[25], which can 299 
be also mediated by CyRPA-specific antibodies. IgM association with higher risk was 300 
reduced after accounting for malaria exposure. However, IgM targeting EBA175-PfF2 at 24 301 
months of age was associated with higher clinical malaria risk, which can be explained by 302 
mechanisms such as IgM masking[38]. Finally, we report that complement fixation by 303 
antibodies targeting MSP119 is associated with protection[33], compared to IgG or IgM levels 304 
against MSP119. This confirms previous results where MSP119, but not MSP3, are targets of 305 
antibodies fixing complement[33], and highlights the importance of studying not only specific 306 
antibody levels, but also functionality of immune responses to not miss any potential 307 
correlate.  308 
 309 
Importantly, correlates of protection were identified only when accounting for heterogeneity in 310 
malaria exposure by (a) including only malaria-exposed individuals; and (b) considering 311 
different exposure levels by clinical, serological and demographic data. By doing so, the 312 
effect of heterogeneous malaria exposure was reduced, and therefore correlates of 313 
protection could be identified. Limiting the follow-up time did not have an impact on our 314 
conclusions when considering malaria exposure, probably by the longer maintenance of 315 
protective immunity in malaria-exposed population, although this approach was shown useful 316 
when exposure variables were not available. This will happen in low transmission contexts 317 
where malaria exposure will be more difficult to define due to the expected drop in clinical 318 
episodes.  319 
 320 
This study has some limitations. First, truly exposed individuals could be excluded from the 321 
analysis, given the restrictive definition of exposure used and the lack of serological data 322 
after 24 months. In this line, the PCD and OM methodologies can lead to underestimate the 323 
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exposed population. However, the study area has an established DSS, that allowed a 324 
rigorous and complete documentation of clinical malaria cases over the study period. 325 
Furthermore, our definition of malaria-exposure included clinical, parasitological and 326 
serological markers (IgMs). Another potential limitation is the methodology to control the 327 
follow-up time. Given that protective thresholds are unknown, the time to 25% of baseline 328 
maternal antibody levels was arbitrarily selected to allow antibodies to decrease while 329 
remaining higher than the seropositivity cutoff. Other limitations include a lacking evaluation 330 
of combination of antibody responses associated with malaria risk and of functional 331 
immunity, that needs to be further studied in bigger populations, with a larger panel of 332 
antigens and including subclasses characterization[32,33,39,40]. This will provide enough 333 
statistical power to identify, if any, more correlates of protection, since unfortunately, 334 
availability of samples was limited. 335 
 336 
Altogether, we report new correlates of clinical malaria protection, and the importance of age 337 
in these studies. We also confirm the crucial requirement to account for heterogeneity in 338 
malaria exposure during vaccine development: from the identification of candidates to the 339 
evaluation of its efficacy. This need will become more apparent as malaria transmission 340 
drops, since the probability of including malaria-unexposed population in clinical trials will 341 
increase. 342 343 Con formato: Fuente: 11 pto
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TABLES  488 
 489 
Table 1. Characteristics of children in the cross-sectional visits.  490 
 Birth 
2,5 
months 5 monhts 
9.5 
months 12 months 24 months p-value 
Age (months) 1 
0.00 
(0.00) 
[143] 
2.60 
(0.09) [71] 
4.73 
(1.12) 
[252] 
9.60 
(0.63) 
[247] 
13.06 
(1.31) 
[256] 
24.16 
(0.42) 
[178] 
- 
Males 2 61 (43%) 32 (45%) 116 (46%) 110 (45%) 118 (46%) 85 (48%) 0.9631 3 
Malaria infection at 
sampling 2 14 (10%) 12 (17%) 25 (10%) 35 (14%) 16 (6%) 66 (37%) < 0.0001 
3 
Cohort 2,4 
A 70 (49%) 71 (100%) 70 (28%) 69 (28%) 72 (28%) 71 (40%) 
< 0.0001 3 
B 0 (0%) 0 (0%) 110 (44%) 108 (44%) 113 (44%) 107 (60%) 
C 73 (51%) 0 (0%) 72 (29%) 70 (28%) 71 (28%) 0 (0%) 
Total 143 (100%) 71 (100%) 
252 
(100%) 
247 
(100%) 
256 
(100%) 
178 
(100%) 
Number of 
previous 
malaria 
episodes 2 
0 143 (100%) 72 (99%) 239 (92%) 202 (77%) 192 (74%) 110 (59%) 
- 
1 0 (0%) 1 (1%) 19 (7%) 37 (14%) 40 (15%) 32 (17%) 
2 0 (0%) 0 (0%) 2 (1%) 13 (5%) 14 (5%) 19 (10%) 
3 0 (0%) 0 (0%) 1 (0%) 8 (3%) 9 (3%) 7 (4%) 
4 0 (0%) 0 (0%) 0 (0%) 1 (0%) 3 (1%) 4 (2%) 
>4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (1%) 15 (8%) 
Malaria-
exposed 
Children by 
Cohort 2,4 
A 41 (56%) 61 (86%) 63 (90%) 59 (86%) 59 (82%) 64 (90%) 
0.0002 5 
B - - 90 (82%) 89 (82%) 95 (84%) 84 (79%) 
C 57 (78%) - 64 (89%) 60 (86%) 65 (92%) - 
Total 98 (69%) 61 (86%) 217 (86%) 208 (84%) 219 (86%) 148 (83%) 
1: Arithmetic Mean (SD) [n] 
2: n (column percentage) 
3: Chi-squared test 
4: See supplementary methods for description 
5: Chi-squared test of “Total” row 
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FIGURE LEGENDS 493 
Figure 1. Boxplots of antibody levels for each cross-sectional visit. For each age 494 
category in ascending order, n = 143, 71, 252, 247, 256, and 178, respectively. MFI: Mean 495 
Fluorescence Intensity.  496 
 497 
Figure 2. Hazard ratios and the 95% confidence interval of clinical malaria for IgG 498 
levels against P. falciparum antigens for children at 9 (a, b) and 24 months (c, d). 499 
Panels (a) and (b) represent the hazards obtained from Cox-regression models adjusted by 500 
infection status, gender, age, neighborhood of residence and cohort. Panels (b) and (d) 501 
represent the hazards obtained from Cox-regression models adjusted by infection status, 502 
gender, age, neighborhood of residence and cohort and that accounted for heterogeneity in 503 
malaria exposure (by excluding non-exposed individuals and adjusting for exposure 504 
variables: number of previous malaria episodes, IgM levels against pre-erythrocytic and 505 
gSG6-P1 antigens at sampling). 506 
 507 
Figure 3. Time to the drop of antibody levels to their 25% levels. The time, in days, to 508 
the drop to a 25% of the antibody levels at birth was calculated with a mixed-effect models 509 
including children from birth to 5 months of age who did not report any infection nor clinical 510 
episode. 511 
